Open Label Study of Long Term Safety Evaluation of Alirocumab To assess the long-term safety of alirocumab when added to lipid-lowering therapy in patients with heterozygous familial hypercholesterolemia (heFH).

• Country None
• organs None
• Specialty None

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer To compare Overall Survival (OS) of patients administered Larotaxel in combination with cisplatin for the treatment of locally advanced/metastatic urothelial tract or bladder cancer

• Country None
• organs None
• Specialty None

Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestrant (Faslodex®) in postmenopausal patients with advanced hormono-dependent breast cancer The primary objective of the study is to evaluate the clinical efficacy of AVE1642 in combination with fulvestrant in terms of clinical benefit (CB) rate defined as the rate of complete responses (CR)...

• Country None
• organs None
• Specialty None

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis Evaluación de Dupilumab en pacientes con poliposis nasal bilateral y síntomas crónicos de sinusitis To evaluate the efficacy of dupilumab in the treatment of bilateral NP by assessment of the endoscopic nasal polyp score in comparison to placebo Evaluar la eficacia de dupilumab en el tratamien...

• Country None
• organs None
• Specialty None

12-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, pharmacodynamic and safety of two doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/day) in the treatment of children and adolescents 2 – 16 years of age with elevated detrusor leak point pressure of neuropathic etiology followed by a 40-week open-label extension ----------------------------------------------------------------------------------------------------- Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, con grupos paralelos y de 12 semanas de duración para investigar la eficacia, farmacodinamia y seguridad de dos dosis de alfuzosina (0,1 mg/kg/día; 0,2 mg/kg/día) en el tratamiento de niños y adolescentes de 2-16 años de edad con elevación de la presión de pérdida del detrusor de etiología neuropática, seguido por una fase de extensión abierta de 40 semanas de duración To evaluate the efficacy of alfuzosin in comparison to placebo on the detrusor leak point pressure (LPP) in children and adolescents 2 – 16 years of age with elevated detrusor leak point pressure of n...

• Country None
• organs None
• Specialty None

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine To demonstrate non-inferiority of SAR342434 versus Humalog in HbA1c change in patients with type 1 diabetes mellitus (T1DM) also using insulin glargine

• Country None
• organs None
• Specialty None

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis To evaluate the efficacy of sarilumab at week 16 in patients with non-infectious uveitis (NIU).

• Country None
• organs None
• Specialty None

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine A SAR342434 és a Humalog® gyors hatású inzulinok összehasonlítása glargin inzulint is alkalmazó, felnőtt, 2-es típusú cukorbetegek körében To demonstrate non-inferiority of SAR342434 versus Humalog in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus (T2DM) also using insulin glargi...

• Country None
• organs None
• Specialty None

Long-Term Safety Evaluation of Dupilumab in Patients with Asthma (LIBERTY ASTHMA TRAVERSE) Evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study

• Country None
• organs None
• Specialty None

Combination of SAR3419 and rituximab in relapsed/refractory Diffuse Large B Cell Lymphoma Objective response rate (Cheson 2007)

• Country None
• organs None
• Specialty None